论文部分内容阅读
达美康系第二代磺脲类口服降糖新药。临床和实践证明本药有较好的降糖作用及减低血小板粘附力的功能,我国已开始用于临床,但对其副作用尚缺乏报道。现将我院收治的1例报道如下。患者,女,63岁,1975年始患糖尿病,多年来用控制饮食,口服降糖灵、优降糖等药物治疗,未用过胰岛素。因尿糖控制不满意于1988年9月16日中午停用其他降糖药改用达美康80mg,每日3次,服药
DaMei Kang Department of second-generation sulfonylurea oral hypoglycemic new drug. Clinical and practice have proved that the drug has a good hypoglycemic effect and reduce platelet adhesion function, China has begun to be used clinically, but its lack of side effects yet to be reported. Now in our hospital one case reported as follows. Patients, female, 63 years old, suffering from diabetes in 1975, over the years with a controlled diet, oral hypoglycemic, glyburide and other drug treatment, not used insulin. Not satisfied with the control of urine glucose in the September 16, 1988 noon to disable other hypoglycemic agents to use Memecan 80mg, 3 times a day, taking medicine